Expert opinion on pharmacotherapy
-
Expert Opin Pharmacother · Mar 2015
Multicenter Study Observational StudyProlonged-release oxycodone/naloxone in opioid-naïve patients - subgroup analysis of a prospective observational study.
Prolonged-release oxycodone/naloxone (OXN PR) showed improved gastrointestinal tolerability and equivalent analgesic efficacy compared to oxycodone alone in patients with non-cancer pain or cancer pain. This is the first dataset to demonstrate its effectiveness and safety compared to other strong opioids in opioid-naïve patients. ⋯ The favorable outcomes under real-life conditions suggest that OXN PR provides a valuable option for treatment of moderate-to-severe pain without using weak opioids first.
-
Expert Opin Pharmacother · Jan 2015
Randomized Controlled Trial Multicenter StudyA multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of single-entity, once-daily hydrocodone tablets in patients with uncontrolled moderate to severe chronic low back pain.
This multicenter, randomized, double-blind, placebo-controlled study with an enriched enrollment, randomized withdrawal design was conducted to evaluate the analgesic efficacy and safety of single-entity, once-daily hydrocodone 20 to 120 mg tablets (HYD) in opioid-naive and opioid-experienced patients with uncontrolled moderate to severe chronic low back pain (CLBP). ⋯ HYD was shown to be an efficacious treatment for CLBP in this study. There were no new or unexpected safety concerns detected.
-
Expert Opin Pharmacother · Jan 2014
Randomized Controlled Trial Multicenter StudyCombined long-acting bronchodilator single therapy for COPD.
In COPD, the long-acting bronchodilators are not always able to provide an appropriate bronchodilator effect in terms of amplitude and duration and this can result in increased severity of respiratory symptoms and in worsening of health status. Combined long-acting bronchodilators can address this limitation. ⋯ Such a combination can provide a superior and sustained bronchodilator effect and can minimize the respiratory symptoms resulting from a suboptimally inhibited bronchoconstriction.
-
Expert Opin Pharmacother · Feb 2013
Randomized Controlled Trial Multicenter Study Comparative StudyBuprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain.
To evaluate the impact of 12 weeks of treatment with Butrans® (buprenorphine) transdermal system (BTDS) on the health-related quality of life (HRQoL) for patients with chronic low back pain (CLBP), and the maintenance of effects over 52 weeks. ⋯ These data suggest that opioid-experienced moderate-to-severe CLBP patients receiving BTDS 20 exhibited better QoL than patients receiving BTDS 5.
-
Expert Opin Pharmacother · Feb 2013
Multicenter Study Clinical TrialThe dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis.
The potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin improves glycemic control in patients with type 2 diabetes through incretin hormone-mediated increases in both α- and β-cell responsiveness to glucose. In this study, the efficacy and safety of alogliptin in type 2 diabetic patients undergoing hemodialysis (HD) were evaluated. ⋯ Alogliptin as monotherapy or in combination with other oral antidiabetic agents improved glycemic control and was generally well tolerated in patients with HD over a 48-week period.